Wegovy was first to market but has been losing ground to Eli Lilly's Zepbound in recent months, according to the latest prescription data. This month, Novo Nordisk has been busy s ...

Wegovy was first to market but has been losing ground to Eli Lilly's Zepbound in recent months, according to the latest ...

Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists of ...

Aetna is once again retreating from the Affordable Care Act market, while its parent company notched a deal with Danish ...

The World Health Organization plans to officially back the use of weight-loss drugs to treat obesity in adults for the first ...

Novo Nordisk ( NVO 0.33%) stock jumped 3.1% at the open Thursday morning before drifting back. As of 10:54 a.m. ET, it was ...

CVS Health raised its full-year profit forecast on Thursday and said it plans to exit the market for Obamacare health ...

CVS Health blew past first-quarter earnings estimates early Thursday, while raising its full-year outlook by a smaller amount. The pharmacy and health benefits giant also announced an agreement to ...

Shares of Novo Nordisk surged after the Danish drugmaker struck an agreement with CVS Health that will let its pharmacy-benefit manager, CVS Caremark, favor the company's weight-loss medication Wegovy ...

This marks a shift in its approach to treating the global obesity problem. Read more at straitstimes.com. Read more at ...

Eli Lilly shares dropped Thursday as Novo Nordisk notched a coverage win for its obesity drug, a sign of the competition in ...

Eli Lilly on Thursday posted better-than-expected quarterly results, although sales of its popular weight-loss drug, Zepbound ...